Organogenesis (ORGO) Scheduled to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is scheduled to be announcing its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.02) per share for the quarter. Organogenesis has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.01. Organogenesis had a return on equity of 2.11% and a net margin of 1.34%. The firm had revenue of $109.98 million for the quarter, compared to the consensus estimate of $100.44 million. During the same quarter last year, the business posted ($0.02) EPS. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organogenesis Stock Performance

ORGO opened at $2.59 on Wednesday. The company has a market capitalization of $343.36 million, a price-to-earnings ratio of 64.77 and a beta of 1.65. The business’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $2.93. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.41. Organogenesis has a 1 year low of $1.96 and a 1 year high of $4.70.

Analysts Set New Price Targets

Separately, Lake Street Capital assumed coverage on Organogenesis in a report on Friday, June 28th. They issued a “buy” rating and a $5.00 price objective for the company.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.